Details
| Stereochemistry | ABSOLUTE |
| Molecular Formula | C20H20ClF3N2O.ClH |
| Molecular Weight | 433.295 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
Cl.FC(F)(F)C1=C(Cl)C(=CC=C1)C(=O)N[C@H]([C@@H]2CCCCN2)C3=CC=CC=C3
InChI
InChIKey=YGCZZYKACZXKHK-AKXYIILFSA-N
InChI=1S/C20H20ClF3N2O.ClH/c21-17-14(9-6-10-15(17)20(22,23)24)19(27)26-18(13-7-2-1-3-8-13)16-11-4-5-12-25-16;/h1-3,6-10,16,18,25H,4-5,11-12H2,(H,26,27);1H/t16-,18-;/m0./s1
| Molecular Formula | C20H20ClF3N2O |
| Molecular Weight | 396.834 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 2 / 2 |
| E/Z Centers | 0 |
| Optical Activity | ( + ) |
| Molecular Formula | ClH |
| Molecular Weight | 36.461 |
| Charge | 0 |
| Count |
|
| Stereochemistry | ACHIRAL |
| Additional Stereochemistry | No |
| Defined Stereocenters | 0 / 0 |
| E/Z Centers | 0 |
| Optical Activity | NONE |
Approval Year
PubMed
| Title | Date | PubMed |
|---|---|---|
| Targeting Glycine Reuptake in Alcohol Seeking and Relapse. | 2018-04 |
|
| Discovery of 3-Chloro-N-{(S)-[3-(1-ethyl-1H-pyrazol-4-yl)phenyl][(2S)-piperidine-2-yl]methyl}-4-(trifluoromethyl)pyridine-2-carboxamide as a Potent Glycine Transporter 1 Inhibitor. | 2016 |
|
| Involvement of the strychnine-sensitive glycine receptor in the anxiolytic effects of GlyT1 inhibitors on maternal separation-induced ultrasonic vocalization in rat pups. | 2015-01-05 |
|
| SSR504734 enhances basal expression of prepulse inhibition but exacerbates the disruption of prepulse inhibition by apomorphine. | 2013-11 |
|
| Inhibition of glycine transporter-1 reduces cue-induced nicotine-seeking, but does not promote extinction of conditioned nicotine cue responding in the rat. | 2013-09 |
|
| Synthesis and evaluation of 2-chloro N-[(S)-{(S)-1-[11 C]methylpiperidin-2-yl} (phenyl)methyl]3-trifluoromethyl-benzamide ([11 C]N-methyl-SSR504734) as a PET radioligand for glycine transporter 1. | 2012-07-09 |
|
| Brain-specific disruption of the eIF2α kinase PERK decreases ATF4 expression and impairs behavioral flexibility. | 2012-06-28 |
|
| Prepulse inhibition of the startle reflex and response to antipsychotic treatments in two outbred mouse strains in comparison to the inbred DBA/2 mouse. | 2011-06 |
|
| In vivo evaluation of carbon-11-labelled non-sarcosine-based glycine transporter 1 inhibitors in mice and conscious monkeys. | 2011-05 |
|
| Amino-terminal isoforms of the human glycine transporter GlyT1 exhibit similar pharmacology. | 2011-02-16 |
|
| Pharmacological characterization of [³H]CHIBA-3007 binding to glycine transporter 1 in the rat brain. | 2011 |
|
| Blockade of glycine transporter 1 by SSR-504734 promotes cognitive flexibility in glycine/NMDA receptor-dependent manner. | 2010-11-23 |
|
| SSR504734, a glycine transporter-1 inhibitor, attenuates acquisition and expression of contextual conditioned fear in rats. | 2010-09 |
|
| Interactions between the glycine transporter 1(GlyT1) inhibitor SSR504734 and psychoactive drugs in mouse motor behaviour. | 2009-08 |
Patents
| Substance Class |
Chemical
Created
by
admin
on
Edited
Tue Apr 01 16:46:53 GMT 2025
by
admin
on
Tue Apr 01 16:46:53 GMT 2025
|
| Record UNII |
L297UZF32G
|
| Record Status |
Validated (UNII)
|
| Record Version |
|
-
Download
| Name | Type | Language | ||
|---|---|---|---|---|
|
Common Name | English | ||
|
Preferred Name | English | ||
|
Systematic Name | English | ||
|
Systematic Name | English | ||
|
Common Name | English |
| Code System | Code | Type | Description | ||
|---|---|---|---|---|---|
|
615571-23-8
Created by
admin on Tue Apr 01 16:46:53 GMT 2025 , Edited by admin on Tue Apr 01 16:46:53 GMT 2025
|
PRIMARY | |||
|
9954539
Created by
admin on Tue Apr 01 16:46:53 GMT 2025 , Edited by admin on Tue Apr 01 16:46:53 GMT 2025
|
PRIMARY | |||
|
L297UZF32G
Created by
admin on Tue Apr 01 16:46:53 GMT 2025 , Edited by admin on Tue Apr 01 16:46:53 GMT 2025
|
PRIMARY | |||
|
300000042454
Created by
admin on Tue Apr 01 16:46:53 GMT 2025 , Edited by admin on Tue Apr 01 16:46:53 GMT 2025
|
PRIMARY |
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
PARENT -> SALT/SOLVATE |
|
| Related Record | Type | Details | ||
|---|---|---|---|---|
|
ACTIVE MOIETY |
We examined the effect of GlyT1 inhibitor SSR-504734 on cognitive flexibility assessed in the attentional set-shifting task in rats (ASST). The second goal was to elucidate whether SSR-504734 effect has been due to the compound's action at glycine/NMDAR site. Rats treated with SSR-504734 (3 and 10 mg/kg, IP) required significantly less trials to criteria during extra-dimensional shift (EDs) phase of the ASST. The effect of SSR-504734 (3 mg/kg) was completely prevented by the glycine/NMDAR site antagonist, L-687,414 (30 mg/kg, IP) that by itself exerted no effect on cognitive flexibility. It is suggested that GlyT1 inhibitors like SSR-504734 may represent a useful pharmacological approach for cognitive enhancement, especially in domains critically affected in schizophrenia.
|
||
|
ACTIVE MOIETY |
Class: Antipsychotic; Mechanism of Action: Glycine transporter 1 inhibitor; Highest Development Phase: Discontinued for Schizophrenia
|
||
|
ACTIVE MOIETY |
Adult rats spent more time exploring the novel than the familiar juvenile. This capacity for social novelty discrimination was impaired in rats that received neonatal PCP treatment and the impaired discrimination could be reversed by acute treatment with antipsychotic drugs such as clozapine (0.3-3 mg/kg) and the glycine transporter GlyT1 inhibitor SSR-504734 (1-10 mg/kg).
|